BD OptiBuildTM BV421 Mouse Anti-Human TIGIT

Description

Multicolor flow cytometric analysis of TIGIT expression on peripheral blood lymphocytes. Whole blood was costained with Alexa Fluor647 Mouse Anti-Human CD56 Cat. No. 557711 , Alexa Fluor488 Mouse Anti-Human CD4 Cat. No. 557695 , BUV395 Mouse Anti-Human CD45RO Cat. No. 564291 or 564292 , and either BD Horizon BV421 Mouse IgG2b, kappa Isotype Control Cat. No. 562748, Top Plots or BD OptiBuild BV421 Mouse Anti-Human TIGIT Cat. No. 747844, Bottom Plots at 0.5 mug/test. After staining, the cells were treated with 1 BD Pharm Lyse Lysing Solution Cat. No. 555899 to remove erythrocytes. Left Plots: The pseudocolor dot plots showing the correlated expression of TIGIT or Ig Isotype control staining versus CD56 were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Right Plots: The pseudocolor dot plots showing the coexpression of TIGIT or Ig Isotype control staining versus CD45RO were derived from gated viable CD4-positive lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Multicolor flow cytometric analysis of TIGIT expression on peripheral blood lymphocytes. Whole blood was costained with Alexa Fluor647 Mouse Anti-Human CD56 Cat. No. 557711 , Alexa Fluor488 Mouse Anti-Human CD4 Cat. No. 557695 , BUV395 Mouse Anti-Human CD45RO Cat. No. 564291 or 564292 , and either BD Horizon BV421 Mouse IgG2b, kappa Isotype Control Cat. No. 562748, Top Plots or BD OptiBuild BV421 Mouse Anti-Human TIGIT Cat. No. 747844, Bottom Plots at 0.5 mug/test. After staining, the cells were treated with 1 BD Pharm Lyse Lysing Solution Cat. No. 555899 to remove erythrocytes. Left Plots: The pseudocolor dot plots showing the correlated expression of TIGIT or Ig Isotype control staining versus CD56 were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Right Plots: The pseudocolor dot plots showing the coexpression of TIGIT or Ig Isotype control staining versus CD45RO were derived from gated viable CD4-positive lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Multicolor flow cytometric analysis of TIGIT expression on peripheral blood lymphocytes. Whole blood was costained with Alexa Fluor647 Mouse Anti-Human CD56 Cat. No. 557711 , Alexa Fluor488 Mouse Anti-Human CD4 Cat. No. 557695 , BUV395 Mouse Anti-Human CD45RO Cat. No. 564291 or 564292 , and either BD Horizon BV421 Mouse IgG2b, kappa Isotype Control Cat. No. 562748, Top Plots or BD OptiBuild BV421 Mouse Anti-Human TIGIT Cat. No. 747844, Bottom Plots at 0.5 mug/test. After staining, the cells were treated with 1 BD Pharm Lyse Lysing Solution Cat. No. 555899 to remove erythrocytes. Left Plots: The pseudocolor dot plots showing the correlated expression of TIGIT or Ig Isotype control staining versus CD56 were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Right Plots: The pseudocolor dot plots showing the coexpression of TIGIT or Ig Isotype control staining versus CD45RO were derived from gated viable CD4-positive lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Show More Multicolor flow cytometric analysis of TIGIT expression on peripheral blood lymphocytes. Whole blood was costained with Alexa Fluor647 Mouse Anti-Human CD56 Cat. No. 557711 , Alexa Fluor488 Mouse Anti-Human CD4 Cat. No. 557695 , BUV395 Mouse Anti-Human CD45RO Cat. No. 564291 or 564292 , and either BD Horizon BV421 Mouse IgG2b, kappa Isotype Control Cat. No. 562748, Top Plots or BD OptiBuild BV421 Mouse Anti-Human TIGIT Cat. No. 747844, Bottom Plots at 0.5 mug/test. After staining, the cells were treated with 1 BD Pharm Lyse Lysing Solution Cat. No. 555899 to remove erythrocytes. Left Plots: The pseudocolor dot plots showing the correlated expression of TIGIT or Ig Isotype control staining versus CD56 were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Right Plots: The pseudocolor dot plots showing the coexpression of TIGIT or Ig Isotype control staining versus CD45RO were derived from gated viable CD4-positive lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Show More Multicolor flow cytometric analysis of TIGIT expression on peripheral blood lymphocytes. Whole blood was costained with Alexa Fluor647 Mouse Anti-Human CD56 Cat. No. 557711 , Alexa Fluor488 Mouse Anti-Human CD4 Cat. No. 557695 , BUV395 Mouse Anti-Human CD45RO Cat. No. 564291 or 564292 , and either BD Horizon BV421 Mouse IgG2b, kappa Isotype Control Cat. No. 562748, Top Plots or BD OptiBuild BV421 Mouse Anti-Human TIGIT Cat. No. 747844, Bottom Plots at 0.5 mug/test. After staining, the cells were treated with 1 BD Pharm Lyse Lysing Solution Cat. No. 555899 to remove erythrocytes. Left Plots: The pseudocolor dot plots showing the correlated expression of TIGIT or Ig Isotype control staining versus CD56 were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Right Plots: The pseudocolor dot plots showing the coexpression of TIGIT or Ig Isotype control staining versus CD45RO were derived from gated viable CD4-positive lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Multicolor flow cytometric analysis of TIGIT expression on peripheral blood lymphocytes. Whole blood was costained with Alexa Fluor647 Mouse Anti-Human CD56 Cat. No. 557711 , Alexa Fluor488 Mouse Anti-Human CD4 Cat. No. 557695 , BUV395 Mouse Anti-Human CD45RO Cat. No. 564291 or 564292 , and either BD Horizon BV421 Mouse IgG2b, kappa Isotype Control Cat. No. 562748, Top Plots or BD OptiBuild BV421 Mouse Anti-Human TIGIT Cat. No. 747844, Bottom Plots at 0.5 mug/test. After staining, the cells were treated with 1 BD Pharm Lyse Lysing Solution Cat. No. 555899 to remove erythrocytes. Left Plots: The pseudocolor dot plots showing the correlated expression of TIGIT or Ig Isotype control staining versus CD56 were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Right Plots: The pseudocolor dot plots showing the coexpression of TIGIT or Ig Isotype control staining versus CD45RO were derived from gated viable CD4-positive lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot.